BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, June 17, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2020

View Archived Issues

Novel NLRP3 inflammasome inhibitors as potential treatments of chronic inflammatory diseases

Read More

First-in-human data reported for Ad5 vectored COVID-19 vaccine

Read More

General method for taking out specific Gram-negatives

Read More

Kinase helps prepare pre-metastatic niche

Read More

Proteostasis Therapeutics reports in vitro data on UPR modulator PTI-129 for COVID-19

Read More

Lilly initiates phase I study of LY-CoV555 for COVID-19

Read More

Sarclisa approved in Europe for adults with relapsed and refractory multiple myeloma

Read More

Danish Medical Agency approves CTA application for AP-1189 in nephrotic syndrome

Read More

Trevena and Imperial College London collaborate to evaluate TRV-027 in patients with COVID-19

Read More

Maximum tolerated dose identified with positive safety profile for CC-92480 in multiple myeloma

Read More

Nimbus Artemis describes new ATP-citrate synthase inhibitors

Read More

FDA clears IND application for SNK-01 in combination with trastuzumab or cetuximab

Read More

MAP3K5 inhibitors discovered at Enanta Pharmaceuticals

Read More

Preliminary safety data reported from ILLUMINATE-206 study

Read More

Bayer patents cytostatic conjugates with integrin alphavbeta3 ligands

Read More

Topline data from pivotal phase III True North trial of Zeposia in ulcerative colitis

Read More

New PI3K-gamma inhibitors disclosed by Incyte

Read More

Beijing Reciproca Pharmaceuticals identifies new Bruton tyrosine kinase inhibitors

Read More

Description of a potential COVID-19 mouse model presenting human ACE2 and TMPRSS2 genes

Read More

Efficacy and safety reported for alflutinib in NSCLC patients with EGFR T790M mutation

Read More

Tenax Therapeutics reports positive phase II results for levosimendan in PH-HFpEF

Read More

Topline data announced from phase IIb study of gusacitinib in chronic hand eczema

Read More

FDA gives clearance to phase I study of CK-0802 in COVID-19-associated ARDS

Read More

Favorable results seen with immunotherapy OH-2 in patients with advanced solid tumors

Read More

Enrollment starts in phase I study of WP-1066

Read More

First-in-human data presented for of SRF-231

Read More

FDA clears IND for phase I/II study of Altimmune's T-COVID

Read More

Intravacc and EpiVax collaborate to advance novel COVID-19 vaccine

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 16, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Genome sequence map

    EHA 2026: With new lenses, a changing view on pediatric cancers

    BioWorld
    In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
  • Medical illustration showing layers of a blood vessel

    Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis

    BioWorld Science
    More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...
  • Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs

    BioWorld Science
    Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing